LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

84.4 -3.55

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

82.74

Максимум

87.35

Ключови измерители
By Trading Economics
Приходи	-8.1M -56M
Продажби	2.9M 60M
EPS	-0.83
Марж на печалбата	-92.559
Служители	414
EBITDA	-9.7M -52M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+55.65% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-96M 5.8B
Предишно отваряне	87.95
Предишно затваряне	84.4

Настроения в новините

By Acuity

60%

40%

270 / 344 Класиране в Healthcare

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.06.2026 г., 20:30 ч. UTC

Печалби

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2.06.2026 г., 23:58 ч. UTC

Пазарно говорене

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2.06.2026 г., 23:41 ч. UTC

Пазарно говорене

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2.06.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2.06.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2.06.2026 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2.06.2026 г., 22:57 ч. UTC

Пазарно говорене

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2.06.2026 г., 22:50 ч. UTC

Пазарно говорене

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2.06.2026 г., 21:07 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.06.2026 г., 21:07 ч. UTC

Пазарно говорене

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2.06.2026 г., 21:00 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

2.06.2026 г., 20:46 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:38 ч. UTC

Печалби

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2.06.2026 г., 20:21 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:12 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Product Rev $594M

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Adj EPS 85c >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Loss $177M >PANW

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

55.65% нагоре

12-месечна прогноза

Среден 136.77 USD 55.65%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

270 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.